

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2015

PRESSURE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of
incorporation)

000-21615
(Commission
File Number)

04-2652826
(IRS Employer
Identification No.)

14 Norfolk Avenue
South Easton, Massachusetts 02375

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (508) 230-1828

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On February 5, 2015, Pressure BioSciences, Inc. (the “Company”) delivered an Investor Presentation at the SeeThruEquity Mid-Winter Investor Conference in New York City. The Company’s February 2015 SeeThruEquity Investor Presentation is attached hereto as Exhibit 99.1.

On February 10, 2015, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.2, announcing that it has received its first purchase order for its new Barozyme HT48 High-throughput System. The Company also announced the receipt of a request for a quotation for the possible purchase of a second Barozyme HT48 System from an existing European customer.

The information contained in this Item 7.01, Exhibit 99.1 and Exhibit 99.2 is being furnished, and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under Section 18. Furthermore, the information contained in this Item 7.01, Exhibit 99.1 and Exhibit 99.2 shall not be deemed to be incorporated by reference into our filings under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Exhibit Description
99.1	Pressure BioSciences, Inc. February 2015 Investor Presentation
99.2	Press Release, dated February 10, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

PRESSURE BIOSCIENCES, INC.

Dated: February 11, 2015

By: /s/ Richard T. Schumacher
Richard T. Schumacher
President

Investor Presentation

Pressure BioSciences, Inc.
(OTCQB: PBIO)

*Discovery Starts
with Sample Preparation™*

SeeThruEquity
Winter Microcap Investor Conference

February 5, 2015

Richard T. Schumacher
President, CEO



Forward Looking Statements

This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company's products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company's filings with the Securities and Exchange Commission.



Company Overview (OTCQB: PBI)

- 10 FT Staff; Near Boston, MA; Publicly Traded (OTCQB: PBI)
- Market Cap (fully diluted): \$8.3Million
- 24 Patents: Pressure Cycling Technology (“PCT”) Platform
- Develop, Mfg, & Sell PCT-based Instruments & Consumables
- Initial Focus in Sample Preparation for the Research Market
- 250 PCT Systems Installed, 150 Customers, 100 Publications
- Early Product Revenue (**through Q3**):
2012 (**\$687,023**) 2013 (**\$746,049**) 2014 (**\$1,084,157**)
- New Instruments (HUB880 and Barozyme HT48) and Consumable (micro-Pestle) Releases in 2014 Expected to Significantly Impact 2015 Revenue



Experienced Senior Management & Board

Management


- **Mr. Richard T. Schumacher, President & CEO**
Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen¹ I Mgr) - Harvard Medical School
- **Dr. Edmund Y. Ting, Senior Vice President of Engineering**
Avure Technologies (CSO); Flow Int¹ I (CSO); Grumman Aerospace; MIT (Ph.D.)
- **Dr. Alexander V. Lazarev, Vice President of R&D**
Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.)
- **Dr. Nathan P. Lawrence, Vice President of Marketing**
Boston Biomedica; BD; Gene-Trak Systems; Yale University (Ph.D.)
- **Mr. Richard P. Thomley, Chief Financial Officer**
Kiva Systems; SynQor; Catamount Manufacturing; ChemDesign Corp

Board

- | | |
|-----------------------------------|--|
| • Jeffrey Peterson, MS | Chairman |
| • Kevin Pollack, Esq., MBA | Audit Committee Chairman |
| • Vito Mangiardi, MBA | Compensation Committee Chairman |
| • Mickey Urdea, Ph.D. | SAB Chairman |
| • Richard T. Schumacher | CEO, Treasurer, Clerk |



Primary Sample Preparation for Biomolecular Analysis: Cell Lysis



PBI

Sample Input Quality = Sample Result Quality



**Scientific research can be broken down to three key elements:
sample preparation, analysis, & data reduction/interpretation**

“Discovery Starts with Sample Preparation”

PBI

Value Proposition: PCT-based biological sample preparation

- Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers – Quality Depends on Quality of Preparation
- Biological Sample Preparation is a Multi-Billion Market Comprised of an Estimated 500,000 Scientists in 80,000 Research Labs WW
- Current Sample Prep Methods are Highly Inadequate: Bottleneck
- Proven Platform: ~ 250 PCT Systems Installed (~150 Sites)
- Over 100 Publications Highlight the Clear Advantages of the PCT Platform Over Current Competitive Products
- **March 2014:** Unveiled First-in-Kind Ultra-HP Instrument (100,000 psi)
- **June 2014:** Unveiled Novel, u-Pestle Consumable for Small Tissue Samples
- **November/December 2014:** Installed the Barozyme HT48 PCT-based System (microwell strips) for Field Evaluation at Three Customer sites (Leading Biotech Company, Georgetown Univ., Feinberg Med School – Northwestern Univ.) for High Throughput Sample Preparation (Protein Digestion)
- **Expect 2015 Revenue to be Significantly Impacted by These New Products**



Biomarker/Forensics Market: Estimated Size

	<u>Estimated Market</u>
• Genomics (DNA/RNA)	\$7.1B in 2015 ^b
• Next Gen Sequencing (DNA)	\$2.7B in 2017 ^c
• Mass Spectrometry (Proteins)	\$2.7B in 2011 ^{a,d}
• Forensic Tools and Products (DNA)	\$17.7B in 2019 ^e
• Sample Prep for all OMICS:	\$8.4B in 2016 ^f
• 500,000 Scientists in 80,000 Biological Research Labs WW ^a	

^a EMMES Group

^b Decisive Bio-Insights

^c Markets & Markets

^d TechNavio

^e Transparency Market Rsh

^f bcc Research



Selected Marquee Customers (150)



HARVARD
MEDICAL SCHOOL



National Institutes
of Health

MONSANTO



BIOGEN

STANFORD
UNIVERSITY



AMGEN



PBI



MERCK



PCT Focus Area: Biomarker Discovery & Forensics

Biomarker Discovery: Cancer, Heart Disease, Stroke, Inf. Diseases, Etc.

Dr. Andreas Huhmer – **Thermo Fisher Scientific**

Dr. Michael Alterman – Tumor Vaccines and Biotechnology Branch, **CBER, FDA**

Dr. Alexander Ivanov – **Harvard School of Public Health**

Dr. Jennifer Van Eyk, **Johns Hopkins School of Medicine**

Dr. Wayne Hubbell, Distinguished Professor, Dept. of Chem & Biochemistry, **UCLA**

Dr. Hans Robert Kalbitzer, Professor, **University of Regensburg**

Dr. Ruedi Aebersold, Institute of Molecular Systems Biology, **ETH Zurich**, Switzerland

Forensics: Improved Processing of Rape Kits, Enhanced DNA Detection

Dr. Bruce Budowle, Health Science Center, **University of North Texas**

Dr. Bruce McCord, **Florida International University**

Dr. Dr. Henry C. Lee, **the Henry C. Lee Institute of Forensic Science**

Competitive Landscape

Nearly All Competitive Methods Involve Mechanical Disruption


- Mortar & Pestle
- Dounce homogenizer (glass on glass)
- Potter-Elvehjem homogenizer (Teflon on glass)
- Enzymatic Digestion
- Polytron shearing homogenizers
- Blenders
- Bead Beating
- Sonication
- Repeated Freeze/Thaw cycles
- French Press (≤ 2000 PSI)



PCT Sample Preparation System



Barocycler™
NEP2320




Barocycler™ NEP3229



PULSE Tube



MicroTubes




PCT-dependent Kits

PBI

The Barrier

Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities.



The Solution (4 years in the making)



**Barozyme HT48 Unveiling
June 2014: ASMS Conf**

**1st Evaluation Shipments
Nov/Dec 2015**

- **Initial Application:**
 - High pressure digestion
- **Consumable:**
 - Proprietary 8-well strips
- **Number of Samples:**
 - 48 samples
- **User Control:**
 - Easy to use touch screen
 - LabView Software

PBI

The Future (is now)



PBI

A Look at Several Scientific and Business Supporters



Prof Wayne Hubbell

- Distinguished Prof: UCLA School of Medicine
- Member, Nat'l Academy of Sciences
- Gold Medal, International EPR Society
- Research: Structure & Function Proteins



Dr. Jennifer Van Eyk

- Prof of Medicine, Cedars-Sinai Med. Ctr.
- Director, Barbara Streisand Women's HC
- Director, NHLBI Prot Innov Ctr, Heart Failure
- Formerly Prof of Medicine, J. Hopkins SoM
- Research: Mechanisms Heart Disease



Mr. David Weild

- Founder, Chairman, CEO: IssuWorks
- Former Vice-Chairman of NASDAQ
- Former Head, Global Equity Trnx, Prud SEC
- Former President, PrudSecurities.com
- Known as "Father of the JOBS Act"

Recent News

- Dec 2014 \$903K PIPE: 30 warrant holders exercised 3,612,000 warrants
- Dec 2014 3rd Barozyme HT48 Evaluation Begins: Feinberg SoM (NW Univ)
- Nov 2014 1st & 2nd Barozyme HT48 Evaluations Begin
- Nov 2014 Q3 Financial Results: Product revenue up, operating costs down
- Oct 2014 Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 Hours Presented

Prof. Ruedi Aebersold said "...working with AB SCIEX we developed a new and improved mass spectrometry method called SWATH, when combined with PCT and consumables (including the u-Pestle) resulted in significantly improved protein data from needle biopsy samples. **We believe PCT SWATH will lead to better analysis of needle biopsy samples in both clinical and research settings, leading to advances in personalized medicine, especially cancer diagnosis and treatment.**



Key Investment Highlights

- Pressure Cycling Technology (PCT): Powerful, Enabling, Patented
- Proven Technology: ~ 250 Installations in ~150 Marquee Laboratories
- Experienced Management Team and Board of Directors
- Large Market Opportunity (est. \$6 Billion; 80k Labs)
- Closed PIPES of \$3.3M (Dec 2013 to Nov 2014) & \$0.9M (Dec 2014)

Short Term Growth Drivers (2015)

- On-going Discussions with Large Potential Strategic Partners
- “Razor/Razorblade” Business Model (Product Rev Up 45% thru Q3 2014)
- Possible Spin-off of Vertical Market Applications
- 2014 Product Releases Expected to Significantly Impact 2015 Revenue
- New Products: HUB880 u-Pestle Barozyme HT48



Breaking News

- **1st High Throughput Barozyme HT48 System Sold!**
 - PO Received on Feb 4th From Evaluation Site #1
 - Leading Biotech Company
 - Already Own and Routinely Use Two Barocyclers
 - Barozyme HT48 Expected Use in Many Depts (R&D, Mfg)
 - Excellent Evaluation Data
- **Quote Requested From European Company**
- **Sites 2 & 3 Continuing Evaluations (data generation)**
- **Sites 4 (MA), 5 (Sweden) & 6 (CA): Q1 2015**

FOR IMMEDIATE RELEASE**Investor Contacts:**

Richard T. Schumacher, President and CEO
Nathan P. Lawrence, Vice President, Marketing and Sales

(508) 230-1828 (T)
(508) 230-1829 (F)

**Pressure BioSciences Receives First Purchase Order
for its Barozyme HT48 High-throughput System*****Evaluation Program to End Early Following Placement of Three Additional Barozyme HT48 Systems; Accelerated Marketing Campaign to Launch Commercialization of the High-throughput PCT-based System***

South Easton, MA, February 10, 2015 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology (“PCT”)-based instruments and consumables to the worldwide life sciences industry, today announced the receipt of the first purchase order for its new Barozyme HT48 High-throughput System. The Company also announced the receipt of a request for a quotation for the possible purchase of a second Barozyme HT48 System; the request came from an existing European customer.

In September 2014, the Company announced plans to build and ship nine Barozyme HT48 High-throughput Systems for independent evaluation. In November and December 2014, the Company announced the installation of the first three evaluation systems. The chosen sites were (i) a leading U.S. biotechnology company, (ii) Dr. Radoslav Goldman’s laboratory at Georgetown University, (ii) Dr. William Funk’s laboratory at the Feinberg School of Medicine (Northwestern University). The purchase order for the Barozyme HT48 System came from the leading U.S. biotechnology company. This Company already owns and routinely uses two NEP2320 Barocycler instruments.

Dr. Nathan Lawrence, VP of Marketing and Sales of PBI, said: “Our evaluation sites have done a terrific job of generating very valuable information in a relatively short period of time. Early results show: (i) the Barozyme HT48 works as well in the hands of independent scientists as it does in our own, (ii) data generated by the Barozyme HT48 are comparable to data generated by the NEP2320, when compared using the same pressure and time parameters, and (iii) data generated using the Barozyme’s BaroFlex 8-well processing strips (which allow the Barozyme HT48 to process up to six strips or 48 samples simultaneously) compare well with data generated using the Company’s existing NEP2320 MicroTube reaction vessel (used to process one sample at a time).”

Dr. Lawrence continued: “Based on the results generated by the evaluation sites, we were able to complete our design optimization with key modifications to both the software and hardware of the Barozyme HT48 System. We believe these improvements will make the Barozyme HT48 System even more versatile, accurate, and robust in serving our customer’s needs. Consequently, we believe the Barozyme HT48 System is now ready for a focused marketing and sales effort.”

Mr. Richard T. Schumacher, President and CEO of PBI said: “We plan to install three more evaluation systems in the coming weeks: one at an academic research facility in MA, one at a cancer research company in CA, and one in a well-known, non-profit research center in Sweden. We expect the three new sites, like the existing three sites, to generate, publish, and present data that we expect will provide strong support to our Barozyme HT48 sales efforts.”

Mr. Schumacher concluded: “Due to the rapid success of the evaluation program, we have decided to end the program early, after six installations and not after the planned nine. This will allow the upgrade of the last three systems with improvements dictated by the evaluation data generated thus far, and to have them ready for sale in the 2015 second quarter. We are excited about this important transition point for PBI.”

About the Barozyme HT48 High-throughput System

The Barozyme HT48 is a first-in-class, high throughput, PCT-based instrument. It is capable of processing up to 48 samples simultaneously using the Company's proprietary BaroFlex 8-well, single-use processing strips. Together, the new Barozyme HT48 instrument and BaroFlex 8-well processing strips make up the Barozyme HT48 High-throughput System (the "Barozyme HT48 System").

The Barozyme HT48 System was designed for rapid, high quality protein digestion - a universally important procedure that the Company estimates is conducted in thousands of laboratories worldwide. The ability of the Barozyme HT48 System to process up to 48 samples simultaneously in the universally accepted "microplate" format is a major improvement in the throughput of sample handling. This is a critical capability needed to interface PCT-based sample preparation smoothly with essential modern laboratory automation. The new BaroFlex format of disposable sample containers in 8-well strips lowers the total cost per sample processed by PCT and facilitates integration of PCT processing with robotic automation essential to the throughput and efficiency of modern laboratories. Lastly, the Barozyme HT48 Systems' computer control was designed to meet GLP compliance demands of biopharmaceutical quality control and clinical proteomics labs.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: P BIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

<http://www.pressurebiosciences.com>

Please visit us on Facebook, LinkedIn, and Twitter